

Agenda

Villa du Lac, Divonne les Bains July 27-28, 2010

Challenges for PDPs in facilitating equitable access to new health products in low income countries

Defining the options and approaches to a discrete set of access-related challenges

Tuesday July 27

9:00 – 9:10	Opening/welcome, and context for the meeting: Elizabeth Gardiner (TB Alliance)
9:10 – 9:30	Access from a country perspective: How are access concerns such as financing, pricing, regulatory issues and decision-making integrated in a country context? Professor Anthony Mbewu (Global Forum for Health Research)
9:30 – 9:45	Access from a donor perspective: Consideration of options and approaches to access-related challenges. Patricia Atkinson (Gates Foundation)
10:00 – 12:00	Defining and developing an appropriate access strategy Moderators: Steve Brooke, Florence Camus Bablon (DNDi) Round table: Key Challenges related to access strategy and options to move forward <ul style="list-style-type: none">• Key challenges in strategy development: Florence Camus Bablon (DNDi)• Defining success and metrics to track progress: Patricia Atkinson(Gates), Elizabeth Gardiner (TB Alliance)• Branding: advantages and disadvantages, is there an optimal solution? Don Douglas (PDVI)• PDP/commercial partnerships: key drivers for optimized success: Steve Brooke (PATH)• How far should the PDPs extend their reach? Elizabeth Gardiner (TB Alliance)• Essential elements of the access strategy: lessons learned: George Jagoe (MMV)
13:15 – 15:15	Country-level decision making: what is the role of a PDP in helping to build country–based consensus around the adoption of a new technology? Moderators: Alan Brooks (Path MVI) & William Wells (TB Alliance) <ul style="list-style-type: none">• Findings from discussion paper; the landscape now and what is needed: William Wells (TB Alliance)• What can PDPs do to facilitate country-led decision making? How should they fit in with contributions from multilaterals, local researchers, NGOs and Pharma companies? Philip Anum (MOH, Ghana)• Case studies from individual PDPs: their vision for decision making, mechanisms for supporting it, reasoning behind those mechanisms and role relative to partners• DNDi and country decision making : a patient and country needs driven initiative: Florence Camus-Bablon (DNDi)• Working with multilaterals as a way to interact with large numbers of countries: Lois Privor-Dumm (IVAC)

	<p>Moderated panel: Alan Brooks (PATH MVI); Philip Anum (MOH Ghana) Florence Camus-Bablon (DNDi); Lois Privor-Dumm (IVAC) with audience participation:</p> <ul style="list-style-type: none"> • Will the number of products being developed by PDPs in the near future overwhelm the capacity for countries to make informed decisions? What can PDPs, countries multilaterals and other actors do to address this potential problem? • What determines the extent of a PDP's involvement in country level decision making: the number of countries with which it interacts directly, and the depth of that interaction? • What determines the choice of partner(s) for country engagement (e.g Multilaterals, local researchers, NGOs, Pharma)?
15:30 – 17:30	<p>The regulatory challenges in ensuring equitable access to new health products in low income countries Moderator: Mike Brennan (AERAS)</p> <ul style="list-style-type: none"> • Highlights of regulatory Discussion paper and presentation of major points for discussion : Mike Brennan (AERAS) • Challenges for regulators in emerging countries: Margareth Ndomondo Sigonda (NEPAD) • Overview of the WHO Regulatory Capacity Building & Prequalification Programmes: Drew Meek (WHO) • Recommendations from the "registering new drugs in the African Context" report: Javier Guzman (George Institute) <p>Moderated Panel Discussion with audience participation: M Sigondo (NEPAD); J Guzman (George Institute); L Rago (WHO); S Chawanon (NHSD Thailand); W Im-Amornphong (Concept Foundation)</p> <p>Discussion will focus on regulatory strategies for PDP products including: mechanisms of approval for products for neglected tropical diseases; information sharing mechanisms among RAs; RA capacity building in emerging countries; novel regulatory strategies e.g joint review</p>
17:30 – 18:00	<p>General discussion and wrap up from Day 1</p>

Wednesday July 28th

8.30-10.30	<p>Pricing as a strategic element of an access strategy Moderator: Evan Lee (FIND)</p> <p>Overview of the range of pricing models available, associated challenges: Prashant Yadev, (MIT-Zaragoza) Reproductive health example: Lester Chinery, (Concept Foundation) Pricing parameters: George Jagoe, (MMV) Benchmarking as pricing model for PDPs :Tom McLean, (IVCC) The pricing parameters recently outlined by GSK and implications: Carla Botting, (PATH MVI) A donor perspective: Patricia Atkinson, (Gates)</p>
10.45-12.30	<p>Economics and Financing Moderator: Lois Privor-Dumm, (IVAC), Johns Hopkins Bloomberg School of Public Health</p> <p>Key issues from discussion paper & case study from the Global Coalition Against Childhood Pneumonia: Lois Privor Dumm (IVAC)</p> <p>1. Economics Should PDPs be responsible for conducting cost effectiveness studies? What can be done to make them more useful for country decision-making purposes? How can cost effectiveness and affordability issues be addressed when multiple interventions may be needed to address a disease?</p> <ul style="list-style-type: none">• CE analyses are important and should be a focus PDPs David Evans, (WHO)• Emphasis of PDPs should be on affordability Tom Mclean, (IVCC) <p>2.Financing All PDPs are going out to donors to get financing for R&D activities. Only some, however, get involved in product financing discussions. Should they be involved and if so, how?</p> <ul style="list-style-type: none">• PDP perspective: Should play a proactive role: Alan Brooks, (PATH MVI)• PDP perspective: Product financing should be the job of the Global Fund or other donor: Tom Mclean, (IVCC)• GAVI perspective: Tania Cernuschi <p>3.Financing How could PDPs work together to expand the pie – is this their role? Is it even realistic that this can happen? Who should be convincing donors to finance more and that multiple interventions may be needed?</p> <ul style="list-style-type: none">• PDP perspective: Alan Brooks, (PATH MVI)• Funder Perspective: Tania Cernuschi
13.15 – 14.00	<p>TDR Implementation research update :Jane Kengeya/Ivane Bochorishvili (TDR)</p> <p>Gates PDP forum update/summary: Patricia Atkinson, (Gates), (PDPs) PDPs: what are the challenges ahead: Javier Guzman (George Institute)</p>
14.15-15.15	<p>Split into working groups (one for each topic) to discuss key questions and draft the key findings, areas for coordination and priorities for next steps</p>
15.15- 16.00	<p>Back to whole group, present conclusions, summary of conclusions and challenges to the PDPs, closing discussion regarding next steps. Moderator: Alan Brooks Close of the main meeting</p>